Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on May 17, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 2,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold at market prices or at negotiated prices through brokers, dealers, or underwriters. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The registration allows Lincoln Park to resell shares of Cingulate Inc.'s common stock that have been or may be acquired through a previously agreed upon Purchase Agreement. The Purchase Agreement provides Lincoln Park the...Show More

Cingulate Inc., a biopharmaceutical company, has filed a Form S-1 with the Securities and Exchange Commission (SEC) on May 17, 2024, for a registration statement under the Securities Act of 1933. This filing pertains to the potential sale of up to 2,000,000 shares of common stock by Lincoln Park Capital Fund, LLC (Lincoln Park), a selling stockholder. The shares may be sold at market prices or at negotiated prices through brokers, dealers, or underwriters. Cingulate Inc. will not receive any proceeds from the sale of shares by Lincoln Park. The registration allows Lincoln Park to resell shares of Cingulate Inc.'s common stock that have been or may be acquired through a previously agreed upon Purchase Agreement. The Purchase Agreement provides Lincoln Park the right to purchase up to $12 million worth of Cingulate Inc.'s common stock, subject to certain conditions and limitations. The filing includes details about the Purchase Agreement, the rights of the selling stockholder, and the use of proceeds from any sales made to Lincoln Park under the agreement. The company's common stock and warrants are listed on the Nasdaq Capital Market under the symbols 'CING' and 'CINGW' respectively.